Haleon PLC Sponsored ADR (NYSE:HLN) Given Average Recommendation of “Hold” by Brokerages

Haleon PLC Sponsored ADR (NYSE:HLN) has been assigned a consensus recommendation of “Hold” from the eleven brokerages that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company.

Several analysts have recently weighed in on the company. Royal Bank Of Canada restated a “sector perform” rating on shares of Haleon in a report on Tuesday. Morgan Stanley reiterated an “overweight” rating on shares of Haleon in a research report on Thursday, August 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a report on Tuesday, June 30th. Rothschild & Co Redburn lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 16th. Finally, Zacks Research lowered shares of Haleon from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 21st.

Haleon Price Performance

Shares of HLN opened at $9.82 on Friday. The firm has a market capitalization of $43.27 billion, a price-to-earnings ratio of 25.19, a price-to-earnings-growth ratio of 1.96 and a beta of 0.12. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.52 and a current ratio of 0.69. Haleon has a one year low of $8.65 and a one year high of $11.28. The stock’s fifty day moving average is $9.60 and its 200-day moving average is $9.84.

Haleon Cuts Dividend

The business also recently announced a dividend, which will be paid on Thursday, September 17th. Investors of record on Friday, August 14th will be issued a $0.0642 dividend. This represents a dividend yield of 131.0%. The ex-dividend date is Friday, August 14th. Haleon’s payout ratio is presently 64.10%.

Institutional Trading of Haleon

Institutional investors and hedge funds have recently bought and sold shares of the stock. Morgan Stanley lifted its stake in Haleon by 16.0% in the 4th quarter. Morgan Stanley now owns 21,495,383 shares of the company’s stock worth $217,318,000 after acquiring an additional 2,962,856 shares in the last quarter. Norges Bank acquired a new position in shares of Haleon in the 4th quarter valued at about $163,529,000. Arrowstreet Capital Limited Partnership lifted its position in shares of Haleon by 82.8% in the first quarter. Arrowstreet Capital Limited Partnership now owns 14,674,518 shares of the company’s stock worth $146,892,000 after purchasing an additional 6,647,329 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Haleon by 116.7% in the second quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock worth $128,423,000 after purchasing an additional 6,669,923 shares in the last quarter. Finally, Sculptor Capital LP boosted its holdings in shares of Haleon by 5.1% during the fourth quarter. Sculptor Capital LP now owns 10,454,868 shares of the company’s stock worth $105,699,000 after purchasing an additional 505,000 shares during the period. Institutional investors and hedge funds own 6.67% of the company’s stock.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over?the?counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self?care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.